SCHEMBL3253095

SCHEMBL3253095

COC(=O)c1[nH]c2ccc(Cl)cc2c1C(N)=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 3/20 0.56
MAP2 P11137 6/20 0.55
TUBB4A P04350 5/20 0.55
TUBB P07437 5/20 0.55
TUBA3C P0DPH7 5/20 0.55
TUBA1B P68363 5/20 0.55
TUBA4A P68366 5/20 0.55
TUBB4B P68371 5/20 0.55
TUBB3 Q13509 5/20 0.55
TUBB2A Q13885 5/20 0.55
TUBB8 Q3ZCM7 5/20 0.55
TUBA3E Q6PEY2 5/20 0.55
TUBA1A Q71U36 5/20 0.55
TUBA1C Q9BQE3 5/20 0.55
TUBB6 Q9BUF5 5/20 0.55
TUBB2B Q9BVA1 5/20 0.55
TUBB1 Q9H4B7 5/20 0.55
ALOX5 P09917 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3262790 0.83 KDM4E (0.53) KDM4EALDH1A1HPGDMAP2TUBB4A
SCHEMBL25751659 0.83 KDM4E (0.58) KDM4EALDH1A1HPGDMAP2TUBB4A
SCHEMBL6162693 0.83 MAP2 (0.50) KDM4EALDH1A1HPGDMAP2
SCHEMBL27442503 0.82 MAP2 (0.59) KDM4EALDH1A1MAP2
SCHEMBL21465510 0.81 KDM4E (0.60) KDM4EALDH1A1HPGDMAP2TUBB4A
SCHEMBL21465557 0.80 TUBB4A (0.65) KDM4EALDH1A1HPGDMAP2TUBB4A
SCHEMBL6308065 0.80 KDM4E (0.58) KDM4EALDH1A1HPGDMAP2TUBB4A
SCHEMBL3246965 0.80 NR4A2 (0.60) KDM4EALDH1A1HPGDMAP2TUBB4A
SCHEMBL5234954 0.78 NR4A2 (0.63) KDM4EALDH1A1HPGDTUBB4ATUBB
SCHEMBL5402454 0.78 ALOX15 (0.60) KDM4EALDH1A1HPGDMAP2TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651639-B1 BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS ARPIDA AG (CH) 2010-05-26 EP disclosed
US-7524854-B2 Benzofuran derivatives and their use in the treatment of microbial infections ARPIDA AG (CH) 2009-04-28 US disclosed
US-20060154943-A1 Benzofuran derivatives and their use in the treatment of microbial infections ARPIDA AG (CH) 2006-07-13 US disclosed
EP-1651639-A1 BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS Arpida AG, (CH) 2006-05-03 EP disclosed
WO-2005005418-A1 BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS ARPIDA AG (CH) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154943-A1 Benzofuran derivatives and their use in the treatment of microbial infections DCXR, NLRP3, NISCH KDM4E 1957/4885ALDH1A1 891/4885HPGD 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.